Schwartz Investment Counsel Inc. Buys New Stake in Phreesia, Inc. $PHR

Schwartz Investment Counsel Inc. acquired a new stake in Phreesia, Inc. (NYSE:PHR) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 49,000 shares of the company’s stock, valued at approximately $1,152,000. Schwartz Investment Counsel Inc. owned 0.08% of Phreesia as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of PHR. Royal Bank of Canada raised its position in Phreesia by 208.8% during the first quarter. Royal Bank of Canada now owns 24,119 shares of the company’s stock valued at $617,000 after acquiring an additional 16,309 shares in the last quarter. AQR Capital Management LLC increased its holdings in shares of Phreesia by 471.2% during the 1st quarter. AQR Capital Management LLC now owns 160,032 shares of the company’s stock valued at $4,090,000 after purchasing an additional 132,015 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Phreesia by 3.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 62,557 shares of the company’s stock valued at $1,599,000 after purchasing an additional 2,158 shares in the last quarter. NewEdge Advisors LLC lifted its stake in shares of Phreesia by 262.7% in the 1st quarter. NewEdge Advisors LLC now owns 15,437 shares of the company’s stock valued at $395,000 after purchasing an additional 11,181 shares during the period. Finally, Goldman Sachs Group Inc. boosted its holdings in Phreesia by 0.4% during the first quarter. Goldman Sachs Group Inc. now owns 600,012 shares of the company’s stock worth $15,336,000 after buying an additional 2,402 shares in the last quarter. 92.10% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Phreesia

In other Phreesia news, General Counsel Allison C. Hoffman sold 6,585 shares of the firm’s stock in a transaction on Thursday, January 8th. The stock was sold at an average price of $17.01, for a total transaction of $112,010.85. Following the completion of the sale, the general counsel owned 174,762 shares of the company’s stock, valued at $2,972,701.62. This trade represents a 3.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider David Linetsky sold 6,106 shares of Phreesia stock in a transaction on Thursday, January 8th. The shares were sold at an average price of $17.01, for a total value of $103,863.06. Following the completion of the sale, the insider owned 231,723 shares in the company, valued at $3,941,608.23. This represents a 2.57% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 31,255 shares of company stock valued at $530,890 over the last ninety days. Corporate insiders own 5.50% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on PHR. Robert W. Baird reduced their price target on shares of Phreesia from $31.00 to $25.00 and set an “outperform” rating for the company in a research report on Wednesday, December 10th. Wells Fargo & Company initiated coverage on Phreesia in a research report on Thursday, January 8th. They issued an “overweight” rating and a $30.00 target price on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Phreesia in a research note on Friday, October 31st. Needham & Company LLC reissued a “buy” rating and issued a $35.00 price objective on shares of Phreesia in a research note on Monday, December 8th. Finally, Mizuho decreased their price objective on Phreesia from $36.00 to $28.00 and set an “outperform” rating on the stock in a report on Wednesday, December 10th. Seventeen research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $30.06.

Phreesia Price Performance

NYSE:PHR opened at $16.42 on Monday. The stock has a 50 day moving average price of $18.36 and a 200 day moving average price of $23.27. The stock has a market cap of $989.96 million, a PE ratio of -164.18 and a beta of 0.61. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.44 and a current ratio of 2.44. Phreesia, Inc. has a one year low of $15.41 and a one year high of $32.76.

Phreesia (NYSE:PHR) last issued its earnings results on Monday, December 8th. The company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.01) by $0.11. Phreesia had a negative return on equity of 1.31% and a negative net margin of 1.16%.The company had revenue of $120.33 million during the quarter, compared to analysts’ expectations of $119.98 million. During the same period in the prior year, the business earned ($0.25) EPS. The firm’s quarterly revenue was up 12.7% on a year-over-year basis. Equities research analysts expect that Phreesia, Inc. will post -1.1 EPS for the current fiscal year.

Phreesia Profile

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.